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Key points
 The TASK-1 channel gene (KCNK3) has been identified as a possible disease-causing gene in
heritable pulmonary arterial hypertension (PAH).
 In the present study, we show that novel mutated TASK-1 channels, seen in PAH patients, have
a substantially reduced current compared to wild-type TASK-1 channels.
 These mutated TASK-1 channels are located at the plasma membrane to the same degree as
wild-type TASK-1 channels.
 ONO-RS-082 and alkaline pH 8.4 both activate TASK-1 channels but do not recover current
through mutant TASK-1 channels.
 We show that the guanylate cyclase activator, riociguat, a novel treatment for PAH, enhances
current through TASK-1 channels but does not recover current through mutant TASK-1
channels.
Abstract Pulmonary arterial hypertension (PAH) affects 15–50 people per million. KCNK3,
the gene that encodes the two pore domain potassium channel TASK-1 (K2P3.1), has been
identified as a possible disease-causing gene in heritable PAH. Recently, two new mutations have
been identified in KCNK3 in PAH patients: G106R and L214R. The present study aimed to
characterize the functional properties and regulation of wild-type (WT) and mutated TASK-1
channels and determine how these might contribute to PAH and its treatment. Currents through
WT and mutated human TASK-1 channels transiently expressed in tsA201 cells were measured
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using whole-cell patch clamp electrophysiology. Localization of fluorescence-tagged channels was
visualized using confocal microscopy and quantified with in-cell and on-cell westerns. G106R
or L214R mutated channels were located at the plasma membrane to the same degree as WT
channels; however, their current was markedly reduced compared to WT TASK-1 channels.
Functional current through these mutated channels could not be restored using activators of WT
TASK-1 channels (pH 8.4, ONO-RS-082). The guanylate cyclase activator, riociguat, enhanced
current through WT TASK-1 channels; however, similar to the other activators investigated,
riociguat did not have any effect on current through mutated TASK-1 channels. Thus, novel
mutations in TASK-1 seen in PAH substantially alter the functional properties of these channels.
Current through these channels could not be restored by activators of TASK-1 channels. Riociguat
enhancement of current through TASK-1 channels could contribute to its therapeutic benefit in
the treatment of PAH.
(Resubmitted 6 October 2018; accepted after revision 24 October 2018; first published online 26 October 2018)
Corresponding author A. Mathie: Medway School of Pharmacy, University of Kent and University of Greenwich, Central
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Introduction
Pulmonary arterial hypertension (PAH, Group 1
pulmonary hypertension) (Simonneau et al. 2013, Galie
et al. 2015) is a progressive and incurable disease that
occurs when the pulmonary arteries undergo pathological
remodelling, causing the blood vessels to vasoconstrict,
with a consequent increase in pulmonary vascular
resistance. Continued high pressure in the pulmonary
artery leads to right ventricular heart failure and death
if left untreated (Gaine & McLaughlin, 2017). Although
PAH is a rare disease with an incidence of 15–50 people
per million in the population (Humbert et al. 2014), the
prognosis for patients is poor, with a 5 year survival rate
of 34% (Tang et al. 2016). PAH can be either idiopathic
(iPAH), heritable/familial (hPAH), or associated with
other pathological conditions such as connective tissue
diseases (e.g. scleroderma), human immunodeficiency
virus (HIV), advanced liver disease, congenital heart
disease and Schistosomiasis infection (Butrous 2015,
Garg et al. 2017, Ghofrani et al. 2017). Despite being
an incurable disease, there are now treatments and
medication that can delay disease progression and
increase life expectancy. Currently, there are three known
pathways that contribute to cell proliferation and vaso-
constriction in the pulmonary arteries: the prostacyclin,
endothelin and nitric oxide pathways. Clinical treatments
are aimed at appropriate up- or down-regulation of
each of these pathways to slow disease progression
(Hill et al. 2016). Recently, riociguat (BAY 63–2521), a
guanylate cyclase stimulator, acting downstream of nitric
oxide through increased cGMP production, has been
approved for use in PAH (Hill et al. 2016, Ghofrani
et al. 2017). The therapeutic benefits of riociguat include
improvement in pulmonary vascular haemodynamics
and increased exercise ability in patients with
PAH.
Advances in DNA sequencing and wide availability of
whole exome sequencing has resulted in a large number of
genetic defects being identified in both hPAH and iPAH
sufferers, enhancing the molecular understanding of the
pathogenic mechanism(s) underlying the disease. Both
hPAH and iPAH have been linked to a defective copy of
the bone morphogenic protein receptor type II (BRPM2)
gene, which regulates vascular cell proliferation (Machado
et al. 2015). Other, less frequent, mutations associated
with PAH include ALK1, ENG, TBX4, EIF2AK4, SMAD,
CAV1 and NOTCH3 (Tang et al. 2016). Additionally, a
number of ion channels have been identified as risk factors
for hPAH and iPAH. In particular, two potassium ion
channels, Kv1.5 (KCNA5) and TASK-1 (KCNK3, K2P3.1),
which are implicated in hPAH and iPAH development,
play a crucial role in regulating pulmonary vascular tone
(Yuan et al. 1998, Boucherat et al. 2015, Hemnes &
Humbert 2017, Olschewski et al. 2017). Down-regulation,
inhibition and mutations of these channels resulting in
loss of channel function have been shown to contribute
to cell proliferation, resistance to apoptosis and vaso-
constriction in pulmonary arterial smooth muscle cells
(PASMCs) (Remillard et al. 2007, Antigny et al. 2016).
Furthermore, a reduction in TASK-1 channel function
has been observed in right ventricular cardiomyoctes
prior to the development of right ventricular hyper-
trophy related to pulmonary hypertension (Lambert
et al. 2018).
TASK-1 channels belong to the two pore domain
family of potassium ion channels (Enyedi & Czirjak
2010). Six heterozygous TASK-1 mutations were first
described in 2013, for both hPAH and iPAH patients
(Ma et al. 2013). Characterization of these mutations
using patch clamp electrophysiology showed that, when
expressed homozygously, these mutations resulted in
loss of channel function. However, the application of a
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phospholipase A2 inhibitor (ONO-RS-O82) was able to
partially restore channel function for two of the homo-
zygous mutant channels, thus opening a new avenue
for PAH-directed therapeutic development (Girerd et al.
2014). This report was followed by the identification of
two further mutations, this time homozygous mutations,
from a Spanish cohort of PAH patients, with an aggressive
form of the disease (Navas et al. 2016).
In the present study, we characterize the functional
properties and membrane localization of the two new
homozygous mutations (G106R and L214R) identified
by Navas et al. (2016). We show that current through
these channels is considerably reduced compared to WT
TASK-1 channels and that functional current through
these mutated channels cannot be restored using activators
of WT TASK-1 channels (pH 8.4, ONO-RS-082). In
addition, we show for the first time that the guanylate
cyclase activator, riociguat, enhances current through WT
TASK-1 channels. Similar to the other activators, however,
riociguat does not have any effect on current through
G106R or L214R mutated TASK-1 channels. A preliminary
account of some of these results has been reported pre-
viously (Cunningham et al. 2017).
Methods
Molecular biology
Human wild-type (WT) TASK-1 (KCNK9) cDNA was
cloned into pcDNA3.1 vector (Invitrogen, Carlsbad, CA,
USA) and was a kind gift from Helen Meadows (Glaxo
SmithKline, Harlow, UK). WT TASK-1 was cut out of
pcDNA3.1 vector and cloned into the MCS of pAc
GFP1-N1 vector (Clontech-Takara Bio Europe, Saint-
Germain-en-Laye, France) to create a fusion construct
with the N-terminus of AcGFP1. The terminating
stop codon of TASK-1 was removed by site-directed
mutagenesis and maintained in the same reading frame
with the start codon of AcGFP1. Constructs were fully
sequencing to ensure correct sequence incorporation
(Eurofins MWG Operon, Huntsville, AL, USA).
Mutations
Point mutations were introduced into both pcDNA3.1 and
pAcGFP1-N1 encoding TASK-1 cDNA by site-directed
mutagenesis using a QuikChange site-directed muta-
genesis kit and procedure (Stratagene, La Jolla, CA,
USA). A pair of complementary oligonucleotide primers
(25–35 bases) incorporating the intended mutation
(either G106R or L214R) were synthesized (Eurofins
MWG Operon, Ebersberg, Germany). All constructs
were fully sequenced to ensure correct mutation
incorporation.
Cell culture
tsA201 cells, which are modified human embryonic
kidney 293 cells stably transfected with the SV40 large
T antigen (ECACC; Sigma-Aldrich, Gillingham, Dorset,
UK), were grown in a monolayer tissue culture flask
maintained in growth medium that was composed of
88% minimum essential media with Earle’s salts, 2 mM
L-glutamine, 10% heat-inactivated foetal bovine serum,
1% penicillin (10,000 units mL−1) and streptomycin
(10 mg mL−1), and 1% nonessential amino acids
(Sigma-Aldrich; Pan Biotech, Aidenbach, Germany; Fisher
Scientific, Pittsburgh, PA, USA). The cells were stored in an
incubator at 37 °C with a humidified atmosphere of 95%
O2 and 5% CO2. When the cells reached 80% confluency,
they were were split and resuspended in a four-well plate
containing glass coverslips (diameter 13 mm) coated with
poly-D-lysine (1 mg mL–1) at a concentration of 7 × 104
cells in 0.5 mL of media, ready for transfection the next
day.
Transfection
For the electrophysiological experiments, cells were trans-
iently transfected using a modified calcium-phosphate
protocol described by Chen & Okayama (1987). Next,
500 ng of pcDNA3.1 vector (Invitrogen) encoding human
WT or mutant human TASK-1 (KCNK3) (Genbank
AF006823) and 500 ng of cDNA encoding for green
fluorescent protein (GFP) was added into each well. The
cells were incubated for 6–8 h at 37 °C in 95% O2 and 5%
CO2. Following incubation, cells were washed twice with
a 1× PBS, and incubated in 0.5 mL of fresh growth media
overnight. The cells were used for electrophysiological
recordings the next day.
For confocal microscopy, cells were transfected
using TurboFect transfection reagent (ThermoFisher,
Loughborough, UK). Then, 1 μg of pAcGFP1-N1 vector
(Clontech-Takara Bio Europe) encoding human WT
or mutant human TASK-1 was diluted in 100 μL
of serum-free cell media. To this, 1.5 μL of the
Turbofect transfection reagent was added and incubated
for 15–20 min. After incubation, this mixture was added to
one well of the plate and incubated for 24–48 h at 37 °C in
95% O2 and 5% CO2, prior to membrane staining and/or
fixation.
Membrane staining
The plasma membranes of cells were stained using
CellMask Deep Red (Thermofisher). A freshly prepared
1:1000 dilution of CellMask Deep Red plasma membrane
stain (1×) was prepared in 1× PBS. Transfected cells were
then washed three times with 1×PBS and submerged into
1 mL of prepared CellMask membrane stain for 5–10 min
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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at 37 °C. The staining solution was removed by washing
the coverslips twice in PBS, ready for fixation.
Cell fixation
Prior to fixation cells were washed twice with room
temperature 1 × PBS and then fixed in 1 mL of 2%
paraformaldehyde (PFA) solution and incubated at 4 °C
for 20 min. Following incubation, the cells were washed
twice in 1 × PBS. For nuclei staining, 500 μL of
freshly prepared Hoechst 33528 (1:500 dilution in PBS;
Sigma-Aldrich) was added to each well and incubated at
37 °C for up to 10 min. Cells were then washed twice
with PBS and rinsed once with ddH2O to remove any
salt crystals. Coverslips were mounted face down onto
slides containing a drop of Vectashield anti-fade mounting
medium (Vector Laboratories, Peterborough UK).
Confocal microscopy
Images were taken using a LSM 880 confocal micro-
scope (Carl Zeiss, Oberkochen, Germany), placed upon
an anti-vibration table and processed using Zen Black
software (Carl Zeiss). Cells were imaged using oil
immersion under a Plan-Apochromat 63×/1.4 oil DIC
M27 objective (Carl Zeiss). The cells were excited with an
argon laser at either 561, 488 or 405 nm for the CellMask
Deep Red plasma membrane stain, pAcGFP-channel and
Hoechst 33528, respectively.
Co-localization analysis
Zen Black software was used to determine the degree
of co-localization. Regions of interest around cells with
detectable green fluorescence were selected for analysis.
Control images for pAcGFP-only cells and Deep Red
membrane stain-only cells were taken with each set of
images to ensure co-localized quadrants were not set
arbitrarily. Pearson’s correlation coefficient (PCC) was
used to represent the degree of co-localization.
In-cell and on-cell western
Cells were seeded onto a poly-D-lysine coated 96-well plate
at a density of 2× 104 cells/well (in 100 μL). The cultures
were incubated for 24 h at 37 °C in 5% CO2 until a
confluence of 80–95% was reached. Each well was trans-
fected with 200 ng of DNA for HA-tagged WT or mutated
TASK1 and 0.4 μL of Turbofect and incubated for 24 h
at 37 °C in 5% CO2. Cell culture media was removed and
cells were immediately fixed with 40 μL of 2% PFA and
incubated at room temperature for 20 min on the bench.
Fixing solution was removed and cells washed.
For staining, cells were incubated 40 μL of a 1:500
dilution of 2 μg μL–1 monoclonal anti-HA antibody
(mouse) in blocking solution. A 1:1000 dilution IRDye
800CW (green) goat anti-mouse secondary antibody
and DRAQ5 (1:10,000; 5 mM) was added to each well.
For whole cell staining (in-cell), the membrane was
permeablized with 40 μL of 0.1% Triton X-100. Plates
were scanned with detection in both the 700 and 800 nm
channels using a Odyssey SA near-infrared fluorescence
imager (Li-Cor, Lincoln, NE, USA). Integrated intensities
were recorded and analysed. For each experiment, each
condition was repeated in triplicate (three coverslips)
and each experiment was repeated on three separate
independent occasions.
Whole-cell patch clamp electrophysiology
Currents were recorded from tsA201 cells transiently
transfected with the channel of interest using whole-cell
patch clamp in a voltage clamp configuration. A coverslip
with transfected tsA201 cells was transferred into a
recording chamber filled with an external solution
composed of (in mM) 145 NaCl, 2.5 KCL, 3 MgCl2, 1 CaCl2
and 10 Hepes (pH to either 7.4 or 8.4, using NaOH),
mounted under an inverted microscope (Diaphot; Nikon,
Tokyo, Japan) with epifluorescence. External solution and
modulatory compounds were superfused at a rate of
4–5 mL min−1. Complete exchange of the bath solution
occurred within 100–120 s. Only cells that were trans-
fected with GFP as evident from green fluorescence
(excitation 395–440 nm; emission 470–600 nm) were
selected for electrophysiological recordings. Patch pipettes
were pulled from thin walled borosilicate glass (GC150TF;
Harvard Apparatus, Edenbridge, UK) and had resistances
of 3–6 M when filled with pipette solution. The pipette
solution contained (in mM) 150 KCL, 3 MgCl2, 5 EGTA
and 10 Hepes (pH adjusted to 7.4 with KOH). Whole-cell
currents were recorded at a holding potential of –60 mV at
20–24 °C (room temperature). Cells were hyperpolarized
to –80 mV for 100 ms and then subjected to a step to
–40 mV for 500 ms, followed by a a step to –120 mV for
100 ms. These step changes were followed by a 500 ms
voltage ramp to +20 mV and a step back to –80 mV for
another 100 ms before returning to the holding potential
of –60 mV. This protocol was composed of sweeps lasting
1.5 s, including sampling at the holding voltage and
was repeated once every 5 s. Currents were recorded
using an Axopatch 200 or 1D patch clamp amplifier
(Molecular Devices, Sunnyvale, CA, USA) and analysed
using pCLAMP, version 10.2 (Molecular Devices), Excel
(Microsoft Corp., Redmond, WA, USA) and Prism,
version 6 or 7 (GraphPad Software Inc., San Diego, CA,
USA). For analysis of outward current, we measured the
current amplitude during the step to−40 mV.
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Chemicals
ONO-RS-082 was purchased from Abcam (Cambridge,
UK) and dissolved in dimethyl sulphoxide (DMSO) to
create a 10 mM stock solution. This was diluted in
external solution to the desired concentration just before
use. Riociguat was purchased from MedChemExpress
(Shanghai, China), diluted in DMSO to create a
10 mM stock. All other chemicals were purchased from
Sigma-Aldrich.
Statistical analysis
Data are expressed as the mean ± 95% confidence inter-
vals (CI) or the mean ± SEM, where n represents the
number of individual cells, and ‘days’ represents the
number of different recording days. On any given day,
recordings were randomized to include both control and
treatment recordings, for both electrophysiological and
imaging experiments. Statistical analysis was performed
using Prism, version 6 or 7 (GraphPad Software Inc.).
Statistical analysis used one-way ANOVA with a post hoc
Dunnett’s test for multiple comparison tests, as well
as paired or unpaired Student’s t tests. P < 0.05 was
considered statistically significant. Where appropriate, the
95% CI for the difference in means is also given.
Results
Structural analysis of the human TASK-1 mutations
TASK-1, which is encoded by the gene KCNK3, belongs
to the two-pore domain potassium (K2P) superfamily of
potassium ion channels. The K2P family of ion channels is
characterized by a unique molecular topology consisting
of two α-subunits that dimerize together to produce a
single central pore, with each α-subunit comprising two
pore (P) loop forming domains and four transmembrane
domains (Enyedi & Czirjak 2010). Two novel pathogenic
missense TASK-1 mutations were identified by Navas et al.
(2016) from three Spanish patients with an aggressive
form of iPAH and hPAH. These mutations c.614 T>G
(L214R) and c.316 G>C G106R were identified on exon 2
of KCNK3 and were the first homozygous mutations to be
reported in PAH (Navas et al. 2016). Using a generic TASK
channel homology model, based on a crystal structure
of the K2P channel TRAAK (Brohawn et al. 2012), the
positions of the two mutations (on the two subunits in
the TASK channel dimer) are indicated in Fig. 1A. The
glycine (G) 106 [mutated to an arginine (R)] is located
extracellularly between the first pore domain and the
second transmembrane domain, whereas the leucine (L)
214 (also mutated to R) is located extracellularly between
the second pore domain and the fourth transmembrane
domain. Alignment of TASK-1 with other members of
the acid-sensitive TASK subfamily (TASK-3 and TASK-5)
shows that these are highly conserved residues and are
probably critical for channel function (Fig. 1B).
Characterization of current through G106R and L214R
mutated human TASK-1 channels
Previously identified mutations of TASK-1 from PAH
patients were found to cause loss of function of the
channel at physiological pH when expressed transiently as
Figure 1. Homology model of TASK-1 variants
A, homology model of TASK channels based on TRAAK crystal structure (PDB ID: 3UM7; Brohawn et al. 2012)
depicting the location of the two PAH TASK-1 mutations: G106R and L214R. TASK-1 G106 amino acids are shown
in red and TASK-1 L214 are shown in blue. Left: side view of the channel. Right: view from above the channel. B,
amino acid sequence alignment of TASK-1 with the two other members of the TASK subfamily: TASK-3 and TASK-5.
Gaps are indicated by dashes and numbers indicate where sequence begins relative to the full length channel. The
amino acids mutated in PAH patients, glycine (G) 106 and leucine (L) 214 are in red and blue, respectively. The
selectivity filter regions are shown in green. [Colour figure can be viewed at wileyonlinelibrary.com]
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homodimer mutants (Ma et al. 2013). Whole-cell patch
clamp techniques were utilized to determine functionality
of the two novel homodimer TASK-1 mutants, G106R and
L214R. Whole-cell recordings from tsA201 cells transiently
transfected with human TASK-1 cDNA gave whole cell
currents of 7.8 pA pF–1 (n = 44 cells from 17 days, 95%
CI = 5.8–9.7) (measured as current density at –40 mV;
see Methods) (Fig. 2A), using a physiological extracellular
solution of 2.5 mM [K+]o. Ramp changes in holding
potential from –120 to +20 mV demonstrate that the
current is outwardly rectifying (Fig. 2B andC) with a mean
zero current potential of –78 mV (n = 44, 95% CI = –74
to –82) close to the equilibrium potential for potassium
ions under these recording conditions. We have shown
previously that TASK-1 channels expressed in tsA201 cells
are enhanced by alkaline pH, blocked by acidic pH and
blocked by methanandamide (Aller et al 2005, Veale et al
2007).
By contrast, mutation of a small uncharged glycine
(G) residue at position 106 to a large positively
charged arginine (R) residue, resulted in a poorly
functioning channel with significantly reduced current,
when expressed alone as a homozygous mutant channel
in tsA201 cells (Fig. 2A–C). The average whole-cell current
measured at –40 mV was 1.8 pA pF–1 (n = 38 cells
from 14 days, 95% CI = 1.3–2.4). Similarly, mutation
of a small hydrophobic leucine (L) residue at position
214 to a large positively charged arginine (R) residue
was found to have substantially reduced current when
expressed alone as a homozygous mutant channel in
tsA201 cells (Fig. 2A–C). The average whole-cell current
measured at –40 mV was 1.6 pA pF–1 (n= 27 cells from 10
days, 95% CI = 1.0–2.3). The outward currents recorded
from TASK-1 G106R and TASK-1 L214R channels were
statistically significantly reduced (P < 0.05, one-way
ANOVA followed by a Dunnett’s multiple comparisons
test) from WT TASK-1 and not significantly different
from untransfected cells. Untransfected tsA201 cells had
an average whole-cell current measured at –40 mV of
1.5 pA pF–1 (n = 36 cells from 9 days, 95% CI = 1.2–1.8)
(Fig. 2A–C).
Outward currents at +20 mV were recorded in
the presence of tetraethylammonium chloride (TEA)
(10 mM) to minimize the contribution of currents
through endogenous KV channels in tsA201 cells. As
for outward currents at –40 mV, currents through both
mutated channels at +20 mV were significantly smaller
than current through WT TASK-1 channels and not
significantly different from cells transfected with GFP
alone (Fig. 2D). Inward currents though WT and mutated
Figure 2. Electrophysiological profiling of currents through WT TASK-1 and TASK-1 mutant channels
A, current density (pA pF–1) measured at –40 mV from individual cells transiently expressing WT TASK-1,
TASK-1 G106R, TASK-1 L214R channels or untransfected cells. Error bars represent the 95% CI. B, raw data
trace from exemplar human TASK-1, TASK-1 G106R, TASK-1 L214R channels and GFP alone transfected cells in
10 mM TEA using a step-ramp voltage protocol as detailed in the Methods. C, current–voltage relationship for the
cells in (B) evoked by ramp changes in voltage from –120 to –20 mV. D, current density (pA pF–1) measured at
+20 mV in the presence of 10 mM TEA for cells expressing WT TASK-1, TASK-1 G106R, TASK-1 L214R channels
or GFP alone. E, current density (pA pF–1) measured at –120 mV in 25 mM K external for cells expressing WT
TASK-1, TASK-1 G106R, TASK-1 L214R channels or GFP alone. F, current density (pA pF–1) measured at –40 mV
for cells expressing WT TASK-1, TASK-1 G106R, TASK-1 L214R channels or co-expression of WT TASK 1 and
TASK-1 G106R or WT TASK 1 and TASK-1 L214R. [Colour figure can be viewed at wileyonlinelibrary.com]
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
J Physiol 597.4 TASK-1 potassium channels and pulmonary arterial hypertension 1093
TASK-1 channels were measured at –120 mV, when the
external solution was raised to 25 mM K to identify inward
current through WT channels (Fig. 3). Again, inward
currents through both mutated channels at –120 mV were
significantly smaller than current through WT TASK-1
channels and not significantly different from cells trans-
fected with GFP alone (Fig. 2E)
Heterodimeric channels
Co-expression of either of the mutated TASK-1
channels with WT TASK-1 channels to allow the
formation of heterodimeric channels gave substantially
and significantly reduced currents from WT TASK-1
channels alone (P < 0.05, one-way ANOVA) that were
not significantly different from mutated channels alone
(Fig. 2F). This suggests that the mutated channels are
dominant negative, when expressed heterologously with
WT TASK-1 channels.
Ion selectivity of WT and mutated TASK-1 channels
Ramp changes in voltage from –120 to +20 mV were
applied to cells expressing WT TASK 1 channels, both of
the mutant channels or GFP alone in normal K external
solution (2.5 mM). The reversal potential of the current
was obtained from these ramps and compared with that
obtained with an external solution containing 25 mM K
(Fig. 2). The external solution was then changed again
to one where 25 mM of Rb or Cs replaced the 25 mM
K. For WT TASK-1 channels, clear shifts in Vrev were
seen compared to recordings in 25 mM K (Fig. 3A and
Table 1). By contrast, no changes in current reversal
potential were seen for either mutant channel in any
condition and the reversal potentials seen were not
significantly different from that seen for cells transfected
with GFP alone (Fig. 3B–D and Table 1).
Cellular localization of fluorescence-labelled TASK-1
variants
To determine whether the reduced current levels recorded
through TASK-1 G106R and TASK-1 L214R variants were
a consequence of reduced trafficking to the plasma
membrane, fluorescence-tagged channels were used to
examine cellular localization. GFP was fused to the C
terminus of TASK-1 and the two TASK-1 variants (see
Methods).
Electrophysiological recordings showed that neither the
GFP tag (9.7 pA pF–1, n = 9 cells, 95% CI = 6.8–12.7
for WT TASK-1 channels vs. 8.2 pA pF–1, n = 8 cells,
95% CI = 4.9–11.5 for pACGFP TASK-1 channels), nor
the different transfection agent (8.0 pA pF–1, n = 5 cells,
95% CI= 5.8–10.1 for CaCl2 transfection vs. 9.5 pA pF
–1,
n = 5 cells, 95% CI = 8.3–10.7 for turbofect trans-
fection), altered the magnitude of functional current
through WT-TASK-1 channels, as measured in temporally
matched experiments.
Cellular localization of WT TASK-1-GFP in tsA201
cells was examined using confocal microscopy. GFP
fluorescence was observed at the plasma membrane
of cells transiently transfected with WT TASK-1-GFP
but there was also expression of WT TASK-1 intra-
cellularly. Figure 4Aa represents a typical cell expressing
TASK-1-GFP fused channels (green), excited at 480 nm.
Fluorescence was also observed for the plasma membrane
Figure 3. Ion permeability of TASK-1
and mutated TASK-1 channels
A–D, current–voltage relationships from
exemplar human TASK-1, TASK-1 G106R,
TASK-1 L214R channels and GFP alone
transfected cells in 2.5 mM K, 25 mM K,
25 mM Rb or 25 mM Cs. [Colour figure can
be viewed at wileyonlinelibrary.com]
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Table 1. The effect of permeating ion on TASK-1 channel current reversal potential
2.5 mM K 25 mM K 25 mM Cs 25 mM Rb
TASK-1 –73 ± 2 (n = 13) –38 ± 1 (n = 10) –64 ± 2 (n = 8) –41 ± 3 (n = 7)
TASK-1 G106R –33 ± 8 (n = 5) –28 ± 4 (n = 5) –29 ± 5 (n = 5) –25 ± 3 (n = 5)
TASK-1 L214R –19 ± 3 (n = 5) –17 ± 2 (n = 5) –18 ± 4 (n = 5) –15 ± 3 (n = 5)
GFP alone –32 ± 2 (n = 13) –25 ± 3 (n = 6) –31 ± 4 (n = 5) –27 ± 3 (n = 5)
Reversal potentials (in mV) obtained for TASK-1, TASK-1 G106R, TASK-1 L214R and GFP alone transfected cells when the external
solution contained 2.5 mM K, 25 mM K, 25 mM Cs or 25 mM Rb.
specific stain, CellMask Deep Red. Figure 4Ab shows
the fluorescence signal (red) for the same cell excited
at 561 nm. Expression of the channel at the membrane
was confirmed by co-localization of the green signal
of the channel with the red signal emitted from the
plasma membrane specific stain (Fig. 4Ac). The nuclei
are stained blue. Co-localization of WT TASK-1 with
the plasma membrane was quantified using PCC from
12 cells, from eight different plates from four different
cultures. A strong linear correlation of 0.65 (n = 12 cells,
95% CI = 0.57–0.73) was observed for WT TASK-1 at
the membrane (Fig. 4E). The same analysis for the two
TASK-1 variants gave results similar to that seen for WT
TASK-1 channels. Strong green fluorescence was observed
at the membrane of cells transiently transfected with
a GFP fused TASK-1 G106R or TASK-1 L214R mutant
channels (Fig. 4Ba and Ca), which showed some overlap
with the red fluorescence from the membrane specific
stain (Fig. 4Bb, Bc, Cb and Cc). PCC values of 0.75
(n = 12 cells, 95% CI = 0.69–0.81 and 0.72 (n = 12 cells,
95% CI = 0.64–0.80 were calculated for TASK-1 G106R
and TASK-1 L214R, respectively (Fig. 4E), which was
not significantly different from WT TASK-1 (P > 0.05,
one-way ANOVA) suggesting that the two variants were
both translated and trafficked to the membrane to the
same degree as WT TASK-1 under these experimental
conditions. In comparison, untransfected cells showed no
green fluorescence (Fig. 4Da–Dc).
In-cell and on-cell westerns
To quantify the expression of WT TASK-1 and mutated
channel protein in the cells and at the membrane,
we used in-cell and on-cell westerns. An HA tag was
engineered between positions alanine (50) and arginine
(51) in the extracellular loop between the first trans-
membrane domain and the first pore region (M1/P1 loop)
of WT TASK-1 channels and the two mutant TASK-1
channels. Thus, the signal seen in unpermeabilized cells
is proportional to the amount of channel expressed at the
cell membrane, whereas the signal in cells permeabilized
with Triton X-100 is proportional to the total number
of channels expressed in the cells. The number of cells
in each coverslip was quantified using DRAQ5, a far-red
DNA stain. Figure 4F shows that there was no significant
difference between the total number cells in coverslips for
WT and mutated channels (DRAQ5 700 nm), the total
amount of TASK channel protein expressed in the cells
(in-cell 800 nm) nor the amount of channel expression at
the cell membrane (on-cell 800 nm) (P > 0.05, two-way
ANOVA). Consistent with previous work (Renigunta et al.
2006, Mathie et al. 2010), the data show that the majority
of TASK-1 channel expression is intracellular, although
the distributions of WT and mutated channels are similar
in transfected cells.
Functional characterization of TASK-1 variants under
conditions of alkalosis
The next step was to characterize the functionality
of these variants using a variety of modulators and
pharmacological tools. TASK-1 channels have a pKa of
7.3 and can be efficiently inhibited and activated by
acidosis or alkalosis, respectively (Duprat et al. 1997).
We investigated whether the TASK-1 variants were still
sensitive to pH changes, as well as whether it was possible
to rescue functionality of these channels, by increasing
extracellular pH from 7.4 to 8.4. As expected for WT
TASK-1 a change in pHo from 7.4 to 8.4 caused a significant
increase in outward current density measured at –40 mV
(P< 0.05, paired t test, 95% CI of difference= 11.6–20.0)
(Fig. 5A–C). For the TASK-1 G106R variant, there was no
significant effect of external alkalosis (P > 0.05, paired t
test, 95% CI of difference = –0.2 to 3.1]) (Fig. 5D–F).
Similarly, for TASK-1 L214R, there was also no significant
effect of external alkalosis (P> 0.05, paired t test, 95% CI
of difference= –1.0 to 1.0]) (Fig. 5G–I).
Effect of ONO-RS-082 on novel TASK-1 variants
It has previously been reported that the phospholipase
A2 inhibitor, ONO-RS-082, was able to rescue current
through two of six heterozygous TASK-1 mutations
identified in patients with PAH (Ma et al. 2013). As
reported by Ma et al. 2013, acute application of 10 μM
ONO-RS-082 to WT TASK-1 resulted in a significant
increase in current density (P< 0.05, paired t test, 95% CI
of difference= 2.3–14.3) (Fig. 6A and B). This effect could
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be reversed in wash (Fig. 6B). By contrast, current density
through the two mutant TASK-1 channels could not be
recovered by ONO-RS-082 using the same experimental
conditions. For TASK-1 G106R, P > 0.05, paired t test,
95% CI of difference=–0.7 to 0.5] and for TASK-1 L214R,
P> 0.05, paired t test, 95% CI of difference= –1.5 to 1.0]
(Fig. 6C–F).
Riociguat-induced enhancement of TASK-1 current
A relatively recent drug licensed for the treatment of PAH,
riociguat belongs to a novel class of pharmacological
agents that directly stimulate soluble guanylate cyclase
(sGC), a key enzyme in the nitric oxide–cGMP signalling
pathway, a major player in the pathophysiology of PAH.
Riociguat stimulates the production of cGMP, which acts
to regulate vascular tone by controlling dilatation and
cellular proliferation of the vascular wall. We aimed to
investigate the action of the sGC stimulator, riociguat,
on WT TASK-1 and the TASK-1 variants. Incubation
of WT TASK-1 channels in either extracellular solution
containing 10μM riociguat or extracellular solution minus
drug for 20 min before recording from cells resulted in
a significant increase in current measured at –40 mV
Figure 4. Evaluation of cellular localization of labelled TASK-1 variants
Aa andAb, photomicrograph taken using confocal microscopy showing cellular localization ofWT TASK-1 channels
C terminally fused with GFP, relative to the location of the plasma membrane stained with CellMask Deep Red. Ac,
overlay of (Aa) and (Ab) indicating co-localization of TASK-1-GFP with the plasma membrane in yellow. Nuclei were
stained with the blue fluorescent dye Hoechst 33258. Ba, cellular localization of TASK-1 G106R fused with GFP,
relative to the location of the membrane (Bb). Bc, co-localization of the G106R variant at the membrane in yellow.
Ca, localization of TASK-1 L214R in relation to the plasma membrane (Cb). Cc, overlap of the GFP-fused variant
with the plasma membrane, stained red. Da, cells untransfected with TASK-1; (Db) and (Dc) as above. All scale
bars are 5 µm. E, quantification of the co-localization observed in experiments, as shown in (Ac), (Bc) and (Cc),
using Pearson’s correlation coefficient. A correlation coefficient of 1 represents 100% correlation. F, integrated
fluorescence intensity for HA-tagged WT and mutant TASK-1 channels in non-permeabilized (membrane) and
permeabilized (whole-cell) cells detected at 800 nm and for DRAQ5 (whole cell) detected at 700 nm using a Li-Cor
Odyssey SA fluorescence imager. Each column represents the mean ± SEM from three independent experiments
performed in triplicate. The mean integrated intensity obtained from untransfected cells on the same plate,
treated in the same way, was subtracted from each value. Inset: exemplar coverslips from a single plate, for ‘no
antib’ (WT TASK-1 with no primary antibody), WT TASK-1, TASK-1 G106R, TASK-1 L214 transfected cells and
untransfected cells ‘untransf’. Each row has three unpermeabilized coverslips and three permeabilized (with Triton
X-100) coverslips. [Colour figure can be viewed at wileyonlinelibrary.com]
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(P< 0.05, unpaired t test, 95% CI of difference= 1.6–8.5)
from 5.8 pA pF–1 (n = 19, 5 days, 95% CI = 3.8–7.8)
for control cells to 10.9 pA pF–1 (n = 17, 5 days, 95%
CI = 7.8–14.0) for cells incubated in riociguat (Fig. 7A
and B). The increased current through TASK-1 channels
in riociguat led to a significant hyperpolarization of the
zero current level (VM) (P< 0.05, unpaired t test, 95% CI
of difference= 7.8–23.0) from –77 mV (95% CI= –72 to
–82) to –93 mV (95% CI= –87 to –99).
Using the same experimental procedure as described
for WT TASK-1, we investigated the effect of riociguat
(10 μM) on the two TASK-1 variants aiming to determine
whether current could be rescued through these mutant
channels. As seen for ONO-RS-082 and pH 8.4, no
increase in functional current by riociguat was observed
for either TASK-1 G106R or TASK-1 L214R. Incubation
of TASK-1 G106R channels in either extracellular solution
containing 10μM riociguat or extracellular solution minus
drug for 20 min before recording from cells resulted in
no significant difference in current measured at –40 mV
(P > 0.05, unpaired t test, 95% CI of difference = –1.7
to 0.3) (Fig. 7C and D). Similarly, incubation of
TASK-1 L214R channels in either extracellular solution
containing 10μM riociguat or extracellular solution minus
drug for 20 min before recording from cells resulted in
no significant difference in current measured at –40 mV
(P > 0.05, unpaired t test, 95% CI of difference = –0.3
to 1.4) (Fig. 7E and F). By contrast to cells expressing
WT channels, riociguat had no significant effect on the
zero current level (VM) of cells expressing TASK-1 G106R
channels (P > 0.05, 95% CI of difference = –12.6 to
5.7) or TASK-1 L214R channels (P > 0.05, 95% CI of
difference= –9.8 to 8.5).
Discussion
In the present study, we report for the first time
the functional consequences of two mutations recently
Figure 5. Effect of extracellular alkalosis on WT TASK-1 and TASK-1 variants
A, plot of currents (pA pF–1) measured at –40 mV, recorded through WT TASK-1 channels in either pH 7.4 (black
dots) or pH 8.4 (green squares). A black line links the same cell in each condition. B, time course plot showing the
effect of pH 8.4 on WT TASK-1 currents. Each point is a 5 s average of the current at –40 mV. Application of pH
8.4 is indicated by the green bar. Current prior to and after the green bar is measured at pH 7.4. C, representative
currents recorded through WT TASK-1 in a single cell, evoked by ramp changes in voltage from –120 to –20 mV
in pH 7.4 (black line) or pH 8.4 (green line). D–F, as shown for (A) to (C), but for TASK-1 G106R channels. G–I, as
shown for (A) to (C), but for TASK-1 L214R channels. [Colour figure can be viewed at wileyonlinelibrary.com]
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reported in PAH patients. We show that current through
two new homozygous mutations (G106R, L214R) of
TASK-1 channels is considerably reduced compared to WT
TASK-1 channels. Although the two mutations of TASK-1
considerably reduce channel current, this is not the result
of any trafficking defects because WT and mutant channels
appear to be equally distributed at the cell membrane.
Instead, the two mutations must alter the functional
properties of TASK-1 channels to reduce current. In both
cases, G106R and L214R, two large positively-charged
arginine residues, are substituted into the channel, close
to the selectivity filter (Fig. 1), which might be hypo-
thesized to interfere with flow of potassium ions through
the channel.
TASK-1 is expressed in rabbit, mouse, human and
rat PASMCs (Gurney et al. 2003, Gardener et al.
2004, Olschewski et al. 2006, Manoury et al. 2009).
The non-inactivating K current in rat, rabbit and
human PASMCs has functional characteristics of TASK-1
channels (Olschewski et al. 2017), although this may not
be the case in mouse PASMCs (Manoury et al. 2009, 2011).
TASK-1 channels are important regulators of PASMC
resting membrane potential and excitability. In rat models
of PAH, TASK-1 current decreased progressively during
development of the disease and this was associated with
a membrane depolarization (Antigny et al. 2016). Indeed,
the results of the present study suggest that reduced
function of TASK-1 channel activity is important in both
hPAH and iPAH.
Pharmacological enhancement of WT TASK-1 current
is observed with both alkaline pH (8.4) and application
of the phospholipase A2 inhibitor, ONO-RS-082. In rat
models of PAH, treatment with ONO-RS-082 reversed the
proliferation, vasoconstriction and inflammation that was
observed (Antigny et al. 2016), indicating the importance
of TASK-1 channels in PAH.
Importantly, in some of the TASK-1 mutations (T8K,
E182K), but not all (e.g. G203D) described by Ma
et al. (2013), ONO-RS-082 was able to restore current
through mutant channels. However, this only occurred
at membrane potentials more positive to the resting
membrane potential of the cells and more positive to
Figure 6. Effect of ONO-RS-082 (10 µM) on
WT TASK-1 and TASK-1 variants
A, a plot of currents (pA pF–1) measured at
–40 mV, recorded through WT TASK-1 channels
in either extracellular recording solution (control)
(black dots) or control solution containing 10 µM
ONO-RS-082 (red squares). A black line links the
same cell in each condition. B, time course plot
showing the acute application of ONO-RS-082
(10 µM) on WT TASK-1 currents. Each point is a
5 s average of the current at –40 mV. Application
of ONO-RS-082 is indicated by the red bar.
Current prior to and after the red bar is
measured in control solution. C and D, as shown
for (A) and (B), but for TASK-1 G106R channels.
E and F, as shown for (A) and (B), but for
TASK-1 L214R channels. [Colour figure can be
viewed at wileyonlinelibrary.com]
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that seen for enhancement of WT TASK-1 current.
Similarly, we have shown previously that current through
the mutated TASK-3 channel (G236R) that underlies
KCNK9 imprinting syndrome (Graham et al. 2016) can
be recovered both pharmacologically through application
of fenamate compounds and genetically through further
gain of function channel mutations (Veale et al. 2014).
These pharmacological interventions restore both current
amplitude and the apparent K selectivity in the channel
(Veale et al. 2014; Bohnen et al. 2017) because, without
the latter, enhancement of a current with reduced
K selectivity would exacerbate any pathophysiological
responses resulting from cellular depolarization, as would
be the case for PASMCs in PAH (Olschewski et al. 2017).
However, neither of the two mutant channels in the present
study showed any recovery of current following exposure
to either alkaline pH or ONO-RS-082.
Although the two mutations in the present study have
been observed as homozygous mutations in patients,
previously identified mutations were heterozygous and
heterozygous channel dimers did display functional
TASK-1 current, although this was considerably reduced
compared to WT TASK-1 (Ma et al. 2013; Bohnen et al.
2017). Current through these heterozygous mutations
could be restored by ONO-RS-082 (Bohnen et al. 2017).
For the two mutations in the present study, current
through heterozygous channels was no larger than that
seen for the homozygous mutants. Furthermore, mutant
TASK-1 channels (such as WT TASK-1 channels) (Czirjak
& Enyedi 2002, Berg et al. 2004, Kang et al. 2004)
could form functional heteromeric channels with TASK-3
channels (Bohnen et al. 2017). Homomeric TASK-1
channels are the predominant TASK channels in PASMCs,
particularly human PASMCs (Olschewski et al. 2006), and
the role of these channels in regulating pulmonary vascular
tone and controlling the resting membrane potential of
these cells is well established in humans (Boucherat et al.
2015). However, in other tissues, such as atrial cardio-
myoctes (Rinne et al. 2015), carotid body glomus cells
(Kim et al. 2009) and cerebellar granule neurons (Aller
et al. 2005), the effect of TASK-1 channel mutations
could be somewhat mitigated through the formation of
functional heterodimers with TASK-3 channel subunits in
these cells.
Figure 7. Effect of Riociguat (10 µm) on WT TASK-1 and TASK-1 variants
A, plot of current (pA pF–1) measured at –40 mV from individual cells transiently expressing WT TASK-1 either
incubated in extracellular solution minus riociguat (control: black dots) or incubated in extracellular solution
containing 10 µM riociguat (blue squares). Error bars represent the 95% CI. B, representative currents recorded
through WT TASK-1, evoked by ramp changes in voltage from –120 mV to –40 mV under control conditions
(2.5 mM [K+]o), (black line) and after incubation in 10 µM riociguat (blue line). C and D, as shown for (A) and (B),
but for TASK-1 G106R channels. E and F, as shown for (A) and (B), but for TASK-1 L214R channels. [Colour figure
can be viewed at wileyonlinelibrary.com]
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The guanylate cyclase activator, riociguat, is approved
for the treatment of PAH. Riociguat catalyses the synthesis
of cGMP, and activates protein kinase G (PKG), which
acts through several putative mechanisms to reduce
intracellular Ca and inhibit smooth muscle contraction
(Ghofrani et al. 2017).
Previous studies have shown that cGMP can enhance
current through both recombinant TASK-1 channels in
expression systems and native TASK-1 currents in basal
forebrain neurons (Kang et al. 2007, Toyoda et al. 2008,
2010). Similarly, TNFα activation of TASK-3 channels
(El Hachmane et al. 2014) is considered to be mediated
through cGMP. It has been proposed that cGMP activates
PKG, which then tunes the pH sensitivity of TASK-1
channels, through PKG-mediated phosphorylation, such
that the phosphorylated channels are less inhibited by H
ions at physiological pH values (Toyoda et al. 2010).
In the present study, we show for the first time that
riociguat enhances current through WT TASK-1 channels,
which could contribute to its therapeutic benefit in PAH.
However, riociguat does not have any effect on current
through G106R or L214R mutated TASK-1 channels.
Whether this is important in terms of the therapeutic
strategy for patients with these mutations will depend
on whether the primary action of riociguat in PAH
is mediated through activation of TASK-1 channels or
whether this is an additional (but beneficial) action of
riociguat (Ghofrani et al. 2017). In this regard, it is of
interest that other regulatory pathways contributing to
cell proliferation and vasoconstriction in the pulmonary
arteries alter the function of TASK-1 channels in PASMCs.
For example, endothelin-1, a potent vasoconstrictor that
stimulates vascular remodelling, inhibits TASK-1 channels
via both a protein kinase C-dependent pathway (Tang
et al. 2009, Schiekel et al. 2013) and Rho kinase (Seyler
et al. 2012). Similarly, treprostinil, a stable analogue of
prostacyclin, acts via PKA to up-regulate TASK-1 current
in human PASMCs (Olschewski et al. 2006).
Down-regulation or inhibition of TASK-1 channel
activity has been proposed to contribute to vascular
remodelling in PAH (Olschewski et al. 2006, Tang
et al. 2009, Antigny et al. 2016) and a loss of TASK-1
channel function and expression is a characteristic of
right ventricular hypertrophy associated with pulmonary
hypertension (Lambert et al. 2018). Guanylate cyclase acti-
vators, endothelin receptor antagonists and prostacyclin
analogues are established vascular therapeutic strategies
in the treatment of PAH, acting to reduce vasoconstriction
and smooth muscle proliferation, and all three will
stimulate activation of TASK-1 channels in PASMCs,
which would contribute to their therapeutic benefit.
In summary, novel mutations in TASK-1 channels
recently seen in PAH are associated with a loss of function.
Current through these channels could not be restored by
activators of TASK-1 channels. Riociguat enhancement of
current through TASK-1 channels could contribute to its
therapeutic benefit in the treatment of PAH.
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